Close

Form 4 Aquestive Therapeutics, For: Aug 16 Filed by: MORRIS TIMOTHY E

August 17, 2022 3:37 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person *
MORRIS TIMOTHY E

(Last) (First) (Middle)
C/O AQUESTIVE THERAPEUTICS, INC
30 TECHNOLOGY DRIVE

(Street)
WARREN NJ 07059

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/16/2022
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right to buy) $ 1.5 08/16/2022   A   28,500     (1) 08/16/2032 Common Stock 28,500 $ 0 28,500 D  
Explanation of Responses:
1. Granted under the Company's 2018 Equity Incentive Plan, which meets the requirements of Rule 16b-3. The options will vest in three annual installments with 1/3% on the 1st installment, 1/3% on the 2nd installment and 1/3% on the 3rd installment.
/s/ Lori Braender, as Attorney-In-Fact 08/17/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
      POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes
and appoints each of Lori J. Braender, A. Ernest Toth, Jr., Valerie Borchevsky
and Ellen S.
Knarr, signing singly, the undersigned's true and lawful attorney-in-fact to:
(i) execute for and on
behalf of the undersigned, in the undersigned's capacity as a director of
Aquestive Therapeutics,
Inc. (the "Company"), a Form ID, including updates thereto, and Forms 3, 4, and
5 in accordance
with Section 16(a) of the Securities Exchange Act of 1934 and the rules
thereunder; (ii) do and
perform any and all acts for and on behalf of the undersigned which may be
necessary or
desirable to complete and execute any such Form ID, including updates thereto,
or Form 3, 4, or
5 and timely file such form with the United States Securities and Exchange
Commission and any
stock exchange or similar authority; and (iii) take any other action of any type
whatsoever in
connection with the foregoing which, in the opinion of such attorney-in-fact,
may be of benefit
to, in the best interest of, or legally required by, the undersigned, it being
understood that the
documents executed by such attorney-in-fact on behalf of the undersigned
pursuant to this Power
of Attorney shall be in such form and shall contain such terms and conditions as
such attorney-in-fact may approve in such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or
proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all
intents and purposes as the undersigned might or could do if personally present,
with full power
of substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact's
substitute or substitutes, shall lawfully do or cause to be done by virtue of
this power of attorney
and the rights and powers herein granted. The undersigned acknowledges that the
foregoing
attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section
16 of the Securities Exchange Act of 1934.
This Power of Attorney shall remain in full force and effect until the
undersigned
is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and
transactions in securities issued by the Company, unless earlier revoked by the
undersigned in a
signed writing delivered to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 12 day of August, 2022.
Timothy E. Morris
    


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings